作者单位:
Chintan V. Dave is a fellow in the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, in Boston, Massachusetts; and an assistant professor at the Center for Pharmacoepidemiology and Treatment Sciences, Rutgers University, in New Brunswick, New Jersey.
[1]
Michael S. Sinha is a fellow at the Harvard-MIT Center for Regulatory Science, part of the Harvard Program in Therapeutic Science at Harvard Medical School, and an affiliated researcher in the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School.
[2]
Reed F. Beall is an assistant professor in the Department of Community Health Sciences and in the O'Brien Institute for Public Health in the Cumming School of Medicine, University of Calgary, in Alberta, Canada, and is affiliated faculty at the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School.
[3]
Aaron S. Kesselheim (akesselheim@bwh.harvard.edu) is a professor of medicine at Harvard Medical School and director of the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School.
[4]
DOI
10.1377/hlthaff.2019.00673
PMID
32479219
发布时间
2021-05-14